| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
MGC Pharmaceuticals Limited (AU: MXC)
MXC Technical Analysis
1
| As on N/A MXC SHARE Price closed @ N/A and we RECOMMEND N/A for LONG-TERM with Stoploss of N/A & N/A for SHORT-TERM with Stoploss of N/A we also expect STOCK to react on Following IMPORTANT LEVELS. |
MXCSHARE Price
| Open | N/A | Change | Price | % |
| High | N/A | 1 Day | N/A | N/A |
| Low | N/A | 1 Week | N/A | N/A |
| Close | N/A | 1 Month | N/A | N/A |
| Volume | N/A | 1 Year | N/A | N/A |
| 52 Week High N/A | 52 Week Low N/A | ||||
AU Australia Most Active Stocks
| SIG | 3.14 | -2.18% |
| PLS | 1.23 | -4.65% |
| EDE | 0.00 | % |
| TLS | 4.89 | -0.61% |
| DRE | 0.01 | 0.00% |
| DTR | 0.08 | 0.00% |
| EVN | 7.82 | 0.51% |
| NWC | 0.06 | 20.00% |
| FBR | 0.00 | % |
| SYA | 0.02 | 100.00% |
AU Australia Top Gainers Stocks
AU Australia Top Losers Stocks
| MXC Daily Charts |
MXC Intraday Charts |
Whats New @ Bazaartrend |
MXC Free Analysis |
|
|
MXC Important Levels Intraday
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE | |
| RESISTANCE |
MXC Forecast June 2025
| 4th UP Forecast | |
| 3rd UP Forecast | |
| 2nd UP Forecast | |
| 1st UP Forecast | |
| 1st DOWN Forecast | |
| 2nd DOWN Forecast | |
| 3rd DOWN Forecast | |
| 4th DOWN Forecast |
MXC Weekly Forecast
| 4th UP Forecast | |
| 3rd UP Forecast | |
| 2nd UP Forecast | |
| 1st UP Forecast | |
| 1st DOWN Forecast | |
| 2nd DOWN Forecast | |
| 3rd DOWN Forecast | |
| 4th DOWN Forecast |
MXC Forecast2025
| 4th UP Forecast | |
| 3rd UP Forecast | |
| 2nd UP Forecast | |
| 1st UP Forecast | |
| 1st DOWN Forecast | |
| 2nd DOWN Forecast | |
| 3rd DOWN Forecast | |
| 4th DOWN Forecast |
MGC Pharmaceuticals Limited ( AU Australia Symbol : MXC )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
MXC Business Profile
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company develops CannEpil, an oral solution to treat refractory epilepsy; Cognicann for the treatment of dementia and Alzheimer's; InCann to treat Chron's and colitis; Tetrinol for the treatment of cachexia; TopiCann to treat dermatitis, rosacea, seborrheic dermatitis, and psoriasis; and CepaCann for the treatment of cerebral palsy. It is also developing phytocannabinoid ratio products, such as MP 100, MP 1:30, MP 1:1, MP 7:1, MP 15:1, and MP 25T. In addition, it develops CimetrA, which is in Phase III for arresting the cytokine storm in COVID-19 patients; and ArtemiC, which is in Phase II clinical trial for the treatment of COVID-19. It has partnership agreements with Royal Melbourne Institute of Technology, the University of Notre Dame, and the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia. Address: 1202 Hay Street, West Perth, WA, Australia, 6005
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service